Altimmune Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, UBS Initiated Coverage on the Stock With a Buy Rating and Announced a Price Target of $26.
Altimmune Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, UBS Initiated Coverage on the Stock With a Buy Rating and Announced a Price Target of $26.
altimmune股票交易更高，因公司報告Q3財務業績好於預期。此外，瑞銀已開始覆蓋該股，並宣佈買入評級，並公佈了26美元的目標價格。
Altimmune Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, UBS Initiated Coverage on the Stock With a Buy Rating and Announced a Price Target of $26.
Altimmune股票交易較高，因公司公佈了超出預期的Q3財務業績。此外，瑞銀已開始對該股進行覆蓋，並公佈了買入評級和目標價26美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間